This study was conducted to investigate immunological components of somatic gene therapy for primary glioblastoma multiforme (GBM) in adults. It involved 13 patients treated by surgical resection of tumor with subsequent radiation therapy. Seven of them received additional herpes simplex virus thymidine kinase/ganciclovir (HSV-tk/GCV) gene therapy by direct intracerebral injection of retrovirus (RV) vector producing cells (VPC) during tumor surgery and subsequent systemic administration of GCV. Peripheral blood for FACS immunophenotyping, isolation of peripheral mononuclear cells (PMNC), and serum ELISA assays for IL-12 and soluble Fas ligand (sFasL) was collected daily during the first 4 post-operative weeks. Tumor specimens were obtained at primary or recurrent surgery and at autopsy. Tumors from gene therapy patients showed varying degrees of peritumoral necrosis around the former tumor resection cavity. Numbers of tumor-infiltrating lymphocytes found
Glioblastoma multiforme (GBM) is a malignant brain tumor entity resistant to neurosurgical treatment, radiation therapy, and chemotherapy. Gene therapy in combination with tumor resection represents an attempt to improve the poor prognosis of GBM patients. The most often used paradigm is the transfer of the herpes simplex virus type 1 thymidine kinase gene (HSV-tk) to tumor cells by recombinant replication-deficient retroviruses (RV). [1] [2] [3] RV are generated and released intratumorally by genetically modified mouse fibroblasts known as virus producer cells (VPC) and stably expressing all retrovirus sequences essential for vector production. 4 Only a few clinical gene therapy studies on GBM patients have been published until now. [5] [6] [7] [8] [9] [10] Most of them were phase I or II investigations to demonstrate the therapeutic safety of this new strategy. The present study was part of the first con-weeks after gene therapy were not significantly increased compared with primary tumors. Mitotic tumor cells were sparse close to the VPC injection sites, but abundant in brain areas somewhat distant from these sites. Serum ELISA revealed significantly increased sFasL and IL-12 levels in the gene therapy group compared with controls. Immunophenotyping of PMNC did not show a significant activation of T cells or NK cells during gene therapy. Interferon gamma secretion was evaluated by ELISPOT assays employing PMNC cocultivated with autologous tumor cells. It demonstrated an antitumor immune response in the gene therapy group, but not in the control group. These findings support the concept of in vivo induction of a systemic immune response by local intracerebral HSV-tk/GCV pharmacogene therapy for primary human GBM. Gene Therapy (2000) 7, 1853-1858.
trolled phase III study RV-mediated HSV-tk/GCV gene therapy for primary GBM.
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To date, the tumoricidal effect of RV-mediated HSV-tk gene transfer has been thought to be mediated exclusively by GCV-induced cytotoxicity to transduced tumor cells 6, 8, 9, 12 and also to their directly attached nontransduced neighbor cells, a phenomenon which is known as the bystander effect. 3, 13, 14 In addition, it has been shown in animal studies that pharmacological gene therapy with HSV-tk/GCV is also able to induce an effective antitumor immune response involving tumor infiltrating T cells and natural killer (NK) cells. [15] [16] [17] [18] [19] This immune response is supposed to enhance the therapeutic effects of pharmacological gene therapy beyond local tumor cell killing, thereby contributing towards the eradication of distant tumor cell foci. However, the clinical trials employing the HSVtk/GCV paradigm did not focus on the possible induction of a therapeutic immune response. 6, 8, 9, 11 Thus, in the present study, therapeutically relevant immunomodulatory effects of retrovirus-mediated HSV-tk/GCV gene therapy in adult GBM patients were investigated and compared with findings in a control group who had undergone the same standard treatment except for gene therapy. The study involved 13 GBM patients, five males and eight females, with a mean age of 60.5 years. Seven patients (three males, four females) received standard treatment with HSV-tk/GCV pharmacogene therapy, and six patients (two males, four females) were treated by standard therapy only. All patients suffered from previously untreated primary GBM suitable to gross total surgical resection. All patients had a Karnofsky score Ͼ70. In the gene therapy group, 0.2-0.5 ml single doses of VPC suspension were injected at multiple sites into the walls of the tumor resection cavity at the end of surgery. The VPC (kindly provided by GTI, Gaithersburg, MD, USA) were murine fibroblasts producing high-titer RV carrying the HSV-tk transgene. 9 VPC had a concentration of 1 × 10 8 cells/ml, and a total volume of 8-9 ml was used for a single case. On day 14 after surgery, intravenous ganciclovir (GCV) treatment was started in patients of the gene therapy group at doses of 5 mg/kg body weight twice a day. Radiation therapy was also commenced on day 14 in all patients. Fractions of 2 Gy were given five times per week for 6 weeks. s.d., standard deviation; G, gene therapy group; C, control group; m, male; f, female. Primary tumor specimens were collected and used for frozen and for paraffin-embedded sections. Diagnosis of GBM was performed on hematoxylin/eosin-stained paraffin-embedded sections. In addition, immunohistochemistry was carried out for GFAP (a glial tumor cell marker), MIB1 (proliferation marker), CD31 (endothelial cell marker), CD45 (pan-leukocyte marker), and HLA-DR (marker for activated microglial cells). In three gene therapy patients, tumor and adjacent tissue specimens were collected 12-34 weeks after primary surgery, either at recurrence surgery or at autopsy, and were processed and evaluated as described above. No analysis of RV-mediated gene transfer to tumor cells was performed in this study. Presence of immunohistochemically positive cells was evaluated in a semiquantitative manner: +, minor immunoreactivity; ++, moderate immunoreactivity; +++, strong immunoreactivity; rec, findings in recurrent tumors; GFAP, glial fibrillary acid protein; NA, not available.
All patients signed an informed consent and agreed to participate in the study. The study protocol was approved by the local ethical committee. Patients were randomly assigned to the gene therapy or control arms (Table 1) . Tumor extent and localization were assessed by contrast-enhanced cranial MRI. All patients received presurgically dexamethasone at doses of 9 to 16 mg/day. Glioblastoma was diagnosed at surgery by frozen sections and confirmed later through light-microscopy in paraffin sections. Specimens obtained from three gene therapy patients with recurrent tumors were investigated in the same way. Analysis of primary tumors demonstrated minor to moderate intratumoral T lymphocytic infiltrates with no significant B cell accumulation, and perivascular populations of activated microglial cells (Table 2 ). Specimens from gene therapy patients obtained at recurrence surgery or autopsy showed varying degrees of tumor necrosis and reactive astrocytic proliferation in and around the former tumor resection cavity, and similar density of tumor-infiltrating lymphocytes compared with the primary tumors ( Figure 1 ). Viable tumor cells were sparse close to the VPC injection sites, but were abundant in the brain areas directly adjacent to the tumor resection borders. Interestingly, the MIB1 immunostaining indicative for mitotic activity was lower in the specimens obtained from tumors after gene therapy than at primary tumor surgery (Figure 1) .
Total counts of PMNC in all patients were markedly decreased before surgery and adjuvant therapy. Numbers of T cells (CD3 + ) and CD4 + or CD8 + T cell subsets (helper and cytotoxic lymphocytes, respectively) did not display a significant increase during GCV therapy (days 14-27), and did not differ significantly in either group of patients (Figure 2a groups, and did not increase significantly during GCV therapy. Similar findings were described with activated NK cells (CD56 + /CD69 + ) in both groups (Figure 2e and f). Serum ELISA measured significantly elevated levels of sFasL in the gene therapy group, especially during GCV therapy (Figure 3a) . In the control group, serum sFasL levels were below the detection limit of the assay (5 pg/ml). IL-12 was found in the serum of both gene therapy and control group patients, but there were statistically significant differences in the concentration of this cytokine in both groups (Figure 3b ). ELISPOT assays for interferon gamma (IFg) secretion demonstrated that there was a significant early (day 7) Th1-type response against VPC cells in gene therapy patients, which declined somewhat over time, but persisted at least until day 28. T cell reactivity against autologous tumor cells was detected in gene therapy patients on day 7 after VPC injection. GCV administration (days 14-27) was followed by a significantly higher antitumor response on day 28 ( Figure 4 ). The reactivity of control patients' PMNCs against VPC and autologous tumor was significantly lower compared with those values in gene therapy patients (Figure 4) .
Barba et al 15 were one of the first to study the immuno- 20 Tumor-specific cytotoxic T cells appeared to be the main component of this cellular response. 19 Ram et al 8 performed one of the first clinical gene therapy studies in recurrent GBM patients. The 15 patients in this trial were treated by chemotherapy and radiation before gene therapy. Because of the very low tumor gene transfer rate, the authors suggested that indirect bystander mechanisms might provide local antitumor activity in human tumors. As possible support for this hypothesis, they found a high titer humoral immune response against RV in the serum of the patients. 8 Other authors reported 30% of cases with humoral immune response against VPC and RV in brain tumor gene therapy patients, 21 and demonstrated that hemorrhagic tumor necrosis due to HSV-tk/GCV gene therapy may stimulate the cellular immune response. 7 The present study shows a systemic immune response targeted against VPC and GBM cells during HSV-tk/GCV pharmacogene therapy in humans. Our observations are in good accordance with recent experiments in mice demonstrating a Th-1 type of immune activation during HSVtk/GCV gene therapy associated with a pronounced cellular immune response (CD4 + and CD8 + T cells) and with increased intratumoral IL-12 levels. 17 Immunosuppressed mice had no such immune response. Cytotoxic responses to HSV-tk expressing cells were greater in animals treated with GCV than those in animals not treated with GCV but harboring intact HSV-TK-positive cells. 17 Analogous to the findings in animals, elevated IL-12 levels in the serum of our gene therapy patients may indicate a systemic Th-1 type immune response. There are data to suggest that serum levels of IL-12 correspond to extent of tumor and to prognosis in cancer patients. 22, 23 In gastrointestinal tumors and other solid cancers, high IL-12 levels in serum may have a favorable prognostic significance and be associated with a longer survival time. 24 High sFasL levels in the serum of our gene therapy patients also indicate a Th-1 response. Soluble FasL has been detected in sera from patients with leukemia, lymphoma, myocarditis, and rheumatic diseases, 25 and therefore it is likely that sFasL functions as a cytotoxic agent in the peripheral immune response. Since sFasL is mainly produced by activated T cells, increased serum levels of sFasL in patients with inflammatory disease and with cancer possibly indicate the activation state of effector T cells. 26 The synergy of HSV-tk/GCV and other pharmacogene therapy systems with radiation therapy has been established in cell culture and in animal experiments. 27, 28 However, there are little data in the literature regarding humans. Recurrent brain tumor patients treated by HSVtk/GCV without simultaneous radiation of tumor area seem to have a stronger immune response than gene therapy patients irradiated during GCV application. Stereotactically injected VPC in previously irradiated patients with recurrent GBM caused a strong systemic cellular immune response with major intratumoral infiltrates of immunocompetent cells. 18 In tumor specimens taken a week after VPC injection, strong macrophage infiltration and perivascular lymphocytic accumulation were observed. Destruction of tumor neocapillaries by HSVtk/GCV therapy caused further intratumoral areas of petechial hemorrhages and ischemic necrosis. 13 Kramm et al 29 studied the systemic immune response during pharmacogene therapy in a 14-year-old patient with recurrent anaplastic ependymoma. During HSV-tk/GCV pharmacogene therapy, no radiation therapy was applied. The authors demonstrated induction of a systemic immune response involving T cell activation and immunostimulatory cytokine release, which were similar to our findings, but more pronounced. Absolute values for IL-12 and sFasL concentration in serum were higher than in our gene therapy group, with peaks of up to 291 pg/ml (day 20). Therefore, we hypothesized that immunosuppressive medication and adjuvant radiation during locally tumor-destructive gene therapy might inhibit the systemic immune response mounted against tumor antigens. Studies comparing immunological findings in parallel groups of tumor patients receiving the same kind of gene therapy, but differing in the type of medication and the timing of adjuvant treatments should provide a better answer to this question.
Our study shows a biphasic release of sFasL with peaks around days 5 and days 15-20 after VPC injection ( Figure  3a ). This may reflect immune response against VPC immediately after injection, which has been also observed in other gene therapy studies by histological or serological methods. 5, 18 After start of GCV administration (day 14), apoptosis onset and presentation of tumor antigens to T cells may lead to the second peak in the immune response, which appears to be tumor-specific. Our ELIS-POT assays also support the hypothesis that gene therapy patients mount an immune response against VPC and, independently of this, also a response against tumor cells. Antitumor response seems to be triggered by HSVtk/GCV destruction of tumor cells. It was somewhat surprising that the IFg response against NIH3T3 fibroblasts was different from the anti-VPC response. It seems possible that a limited number of antigens present in VPC and absent in NIH3T3, such as RV structural proteins or HSV-tk, are targeted. This hypothesis is supported by findings in humans, which demonstrate an immune response against RV proteins after grafting of VPC. 8, 9, 18 The innate immunity of humans against xenogeneic antigens explains the PMNC response when incubated with murine NIH3T3 cells. 30 In conclusion, our findings, as well as previous reports [15] [16] [17] [18] on an immunological component of HSVtk/GCV gene therapy may reveal an additional effect of pharmacogene therapy: destruction of tumor cells by bioactivated drugs provides tumor antigen release without suppression of antitumor immune response, as with conventional chemotherapy or radiation. Apoptotic tumor cell death with concomitant activation of the immune system may represent an effective antitumor vaccination strategy in vivo. Our data support the feasi- bility of a future approach relying on a strong systemic antitumor immune response by combination of pharmacological and immunological gene therapy.
